Linked Life Data

16246622

Source:http://linkedlifedata.com/resource/pubmed/id/16246622

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-11-21
pubmed:abstractText
Tuberculosis remains a major health threat, solved by neither chemotherapy nor the current vaccine, BCG. Although a new generation of vaccine candidates is ready for field trials, further improvements will be required. A successful vaccination regime must stimulate memory T cells and, at the same time, avoid exhaustion of memory and suppression by regulatory mechanisms. The most probable scenario is priming with one vaccine candidate followed by boosting with a another vaccine candidate. For clinical trials, biomarkers need to be defined with T cells alternating between lung and periphery as prime indicator cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1471-4906
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
660-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Recent findings in immunology give tuberculosis vaccines a new boost.
pubmed:affiliation
Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21-22, 10117 Berlin, Germany. kaufmann@mpiib-berlin.mpg.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't